1136-1137 / 1578
Oligometastases: prostate cancer
•
363 patients, 9 studies; 211 treated with SBRT to 270 lymph nodes
•
Mean BED
3Gy
in fractionated SBRT ranged from 88-216 Gy
•
Median follow-up of 19.2 months; local control in 98% of patients.
•
Median Pprogression Free Survival (biochemical and/or radiological
progression) 22.5 months (range, 11-30)
•
Median ADT-free survival was 32.8 months (range, 25-44)
•
Acute and/or late grade ≥2 toxicity in 6%; no grade 4 toxicity
CONCLUSIONS:
•
SBRT is promising but weak level of evidence based on retrospective studies
of single-institution or pooled experiences
Systematic review: SABR in oligorecurrences limited to lymph nodes
Ponti E, Eur Urology Focus 2017